Cookies?
Library Header Image
LSE Research Online LSE Library Services

Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

Malmström, Rickard E., Godman, Brian B., Diogene, Eduard, Baumgärtel, Christoph, Bennie, Marion, Bishop, Iain, Brzezinska, Anna, Bucsics, Anna, Campbell, Stephen, Ferrario, Alessandra, Finlayson, Alexander E., Fürst, Jurij, Garuoliene, Kristina, Gomes, Miguel, Gutiérrez-Ibarluzea, Iñaki, Haycox, Alan, Hviding, Krystyna, Herholz, Harald, Hoffmann, Mikael, Jan, Saira, Jones, Jan, Joppi, Roberta, Kalaba, Marija, Kvalheim, Christina, Laius, Ott, Langner, Irene, Lonsdale, Julie, Lööv, Sven-Äke, Malinowska, Kamila, McCullagh, Laura, Paterson, Ken, Markovic-Pekovic, Vanda, Martin, Andrew, Piessnegger, Jutta, Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Tulunay, Cankat, Tomek, Dominik, Vončina, Luka, Vlahovic-Palcevski, Vera, Wale, Janet, Wilcock, Michael, Wladysiuk, Magdalena, Woerkom, Menno van, Zara, Corrine and Gustafsson, Lars L. (2013) Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Frontiers in Pharmacology, 4 (39). ISSN 1663-9812

Full text not available from this repository.
Identification Number: 10.3389/fphar.2013.00039

Abstract

There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst new effective treatments are needed, there are issues in the elderly with dabigatran due to variable drug concentrations, no known antidote and dependence on renal elimination. Published studies have shown dabigatran to be cost-effective but there are budget concerns given the prevalence of AF. There are also issues with potentially re-designing anticoagulant services. This has resulted in activities across countries to better manage its use.

Item Type: Article
Official URL: http://www.frontiersin.org/Pharmaceutical_Medicine...
Additional Information: © 2013 The Authors
Divisions: Social Policy
LSE Health
Subjects: R Medicine > RM Therapeutics. Pharmacology
Sets: Departments > Social Policy
Research centres and groups > LSE Health
Date Deposited: 30 Aug 2013 13:48
Last Modified: 20 Jun 2019 01:48
Funders: Karolinska Institutet, Sweden
URI: http://eprints.lse.ac.uk/id/eprint/52178

Actions (login required)

View Item View Item